Hives in autonomic disorders: a cutaneous marker of a distinct symptom phenotype

Chatuthanai Savigamin, Tae Chung, Alison W. Rebman, Yanni Larsen, Maarten Sap, Erica Cerquetti, Christina Kokorelis, Pegah Dehghan, Peter C. Rowe, Brittany L. AdlerAnnals 2026 · DOI

TL;DR

This study reveals that hives are a common and significant symptom in patients with postural orthostatic tachycardia syndrome (POTS) and neurally-mediated hypotension (NMH), often indicating a more severe symptom burden. The findings suggest that hives may serve as a visible marker for a distinct subtype of autonomic dysfunction, potentially linked to mast cell activation, which could inform new diagnostic and therapeutic approaches.

What Problem Does This Paper Address?

Orthostatic intolerance, particularly POTS and NMH, are complex autonomic disorders with a wide range of symptoms that are not fully understood. While mast cell activation syndrome (MCAS) has been anecdotally linked to POTS, its prevalence and clinical significance within these autonomic disorders remain poorly defined. The authors aim to investigate the frequency of hives, a common manifestation of mast cell activation, in a cohort of POTS and NMH patients and to determine if hives are associated with specific symptom profiles or clinical characteristics. This research seeks to clarify whether hives represent a distinct clinical phenotype within these syndromes, potentially pointing towards mast cell involvement as a contributing factor.

Methods

This study employed a cross-sectional design, collecting data from 188 patients at the Johns Hopkins POTS Clinic. Participants completed electronic questionnaires assessing hives frequency, overall symptom burden using the Malmö POTS questionnaire, and autonomic symptom severity using the Composite Autonomic Symptom Score (COMPASS-31). Additional clinical data, including diagnoses, medications, autonomic testing results (tilt table tests, 10-minute stand tests), and skin biopsies for nerve fiber density, were retrospectively abstracted from medical records. Statistical analyses included descriptive statistics, chi-square tests, Fisher's exact tests, Kruskal-Wallis tests, and multivariable linear regression to examine associations between hives and various clinical and demographic factors.

Datasets

The study utilized data from 188 patients diagnosed with POTS, NMH, or clinically significant orthostatic intolerance. This dataset was collected through electronic questionnaires and retrospective chart reviews. No new benchmarks were introduced; the study focused on analyzing existing clinical data and patient-reported outcomes.

Key Insights and Ideas

  • Hives as a "Red Flag": The presence and frequency of hives are not just incidental symptoms but are significantly associated with a greater overall symptom burden in patients with POTS and NMH. This suggests hives could be a valuable clinical indicator.
  • Beyond Orthostatic Symptoms: The study highlights that the symptom burden associated with hives extends beyond typical orthostatic intolerance symptoms, encompassing significant gastrointestinal, urinary, and vasomotor issues, as well as neuropathic pain. This points to a broader, potentially systemic, involvement.
  • Potential Link to Mast Cell Activation: The strong association of hives with symptoms suggestive of mast cell activation (like GI and urinary issues) and the known interplay between mast cells and the autonomic nervous system provide compelling, albeit preliminary, evidence for mast cell involvement in a subset of these patients.
  • Neuropathic Pain Connection: Hives are strongly linked to various types of pain, including burning, pressure, and electric shock pain, and tingling. This suggests a potential shared pathway or mechanism contributing to both cutaneous and neuropathic symptoms.

Key Results

  • Prevalence: A substantial majority of patients reported experiencing hives, with 60.1% reporting them sometimes, often, or always. Specifically, 42.6% reported hives "sometimes," and 17.6% reported them "often or always."
  • Symptom Burden: Increasing frequency of hives was significantly associated with higher scores on the Malmö POTS questionnaire (indicating greater symptom burden) and higher scores in the gastrointestinal, bladder, and vasomotor subdomains of the COMPASS-31.
  • Pain and Tingling: Patients with hives were significantly more likely to report experiencing pain (OR 3.47) and tingling (OR 5.73). Specific pain types like burning, pressure, and electric shock pain were also more prevalent in those with hives.
  • Demographics: Hives were significantly associated with female sex (OR 4.34), but not with age, race, or specific autonomic diagnoses (POTS, NMH).
  • Associated Diagnoses: Patients with hives were more likely to have a diagnosis of Mast Cell Activation Syndrome (MCAS) or Ehlers-Danlos Syndrome (EDS).
  • Objective Measures: While an association was found between hives and intraepidermal nerve fiber density at the distal leg, this did not remain significant after adjusting for age. No significant associations were found between hives and autonomic testing parameters (heart rate changes, heart rate variability, Valsalva ratio).

Limitations and Future Work

The authors acknowledge several limitations:

  • Non-standardized Autonomic Testing: Tilt table test protocols varied, potentially leading to diagnostic uncertainty between POTS and NMH.
  • Lack of Control Group: The study did not include a non-POTS/NMH control group, making it difficult to definitively conclude that hives, flushing, and pain are more common in these populations compared to the general population.
  • Self-Reported Hives: Hives were self-reported rather than physician-confirmed, which could introduce bias.
  • Low Response Rate: The response rate to the questionnaires was relatively low (23.4%), potentially introducing sample bias.

Future work suggested by the authors includes:

  • Clarifying Mechanisms: Further research is needed to elucidate the precise mechanisms linking autonomic dysfunction and mast cell activation.
  • Standardized Protocols: Future studies should utilize standardized autonomic testing protocols to better differentiate between POTS and NMH.
  • Investigating Triggers: Characterizing potential triggers for hives (e.g., heat, stress) and their temporal relationship with POTS/NMH symptoms is crucial.
  • Mast Cell-Targeted Therapies: Evaluating the efficacy of mast cell-directed therapies for patients with this hive-associated phenotype is a promising therapeutic avenue.
  • Objective Immunologic Profiling: Incorporating objective autonomic testing and immunologic profiling will be essential for a more precise understanding of these conditions.

Summary updated

Abstract

Hives are common in orthostatic intolerance syndromes and are associated with increased symptom burden. Future studies are needed to clarify the role of mast cell activation and evaluate mast cell-targeted therapies.
BibTeX
@article{savigamin2026hives,
  author = {Chatuthanai Savigamin and Tae Chung and Alison W. Rebman and Yanni Larsen and Maarten Sap and Erica Cerquetti and Christina Kokorelis and Pegah Dehghan and Peter C. Rowe and Brittany L. Adler},
  title = {{Hives in autonomic disorders: a cutaneous marker of a distinct symptom phenotype}},
  journal = {Annals},
  year = {2026},
  doi = {10.1080/07853890.2026.2626224},
}
Figure